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Background: Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety
and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis
(RA).
Methods: Eligible patients had previously completed a phase 1, 2, or 3 qualifying index study of tofacitinib and
received open-label tofacitinib 5 mg or 10 mg BID. Stable background therapy, including csDMARDs, was continued;
adjustments to tofacitinib or background therapy were permitted at investigators’ discretion. Assignment to dose
groups (5 mg or 10 mg BID) was based on patients’ average total daily dose. The primary objective was to
determine the long-term safety and tolerability of tofacitinib 5 mg and 10 mg BID; the key secondary objective was
to evaluate the long-term persistence of efficacy.
Results: Between February 5, 2007, and November 30, 2016, 4481 patients were enrolled. Total tofacitinib exposure
was 16,291 patient-years. Safety data are reported up to month 114 for all tofacitinib; efficacy data are reported up
to month 96 for tofacitinib 5 mg BID and month 72 for 10 mg BID (with low patient numbers limiting interpretation
beyond these time points). Overall, 52% of patients discontinued (24% due to adverse events [AEs] and 4% due to
insufficient clinical response); the safety profile remained consistent with that observed in prior phase 1, 2, 3, or LTE
studies. The incidence rate (IR; number of patients with events per 100 patient-years) for AEs leading to discontinuation
was 6.8. For all-cause AEs of special interest, IRs were 3.4 for herpes zoster, 2.4 for serious infections, 0.8 for malignancies
excluding non-melanoma skin cancer, 0.4 for major adverse cardiovascular events, and 0.3 for all-cause mortality. Clinically
meaningful improvements in the signs and symptoms of RA and physical functioning, which were observed in the index
studies, were maintained.
Conclusions: Tofacitinib 5mg and 10mg BID demonstrated a consistent safety profile (as monotherapy or combination
therapy) and sustained efficacy in this open-label LTE study of patients with RA. Safety data are reported up to 9.5 years,
and efficacy data up to 8 years, based on adequate patient numbers to support conclusions.
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Rheumatoid arthritis (RA) is a chronic and debilitating
autoimmune disease characterized by systemic inflam-
mation, persistent synovitis, and joint destruction, and
affects an estimated 0.24% of the global population [1].
Tofacitinib is an oral Janus kinase inhibitor for the
treatment of RA. The efficacy and safety of tofacitinib
5mg and 10mg twice daily (BID) administered as mono-
therapy or in combination with conventional synthetic
disease-modifying antirheumatic drugs (csDMARDs),
mainly methotrexate (MTX), in patients with moderately
to severely active RA, have been demonstrated in phase
2 [2–6] and phase 3 [7–13] randomized controlled trials
(RCTs) of up to 24 months’ duration.
The efficacy and safety of therapy is typically evaluated
via double-blind RCTs. As RA is a chronic disease re-
quiring long-term treatment, it is important to assess
the long-term effectiveness and safety of RA therapies to
understand the potential lifelong impact on patients’
health and quality of life. Of note, long-term extension
(LTE) studies, with their controlled setting and rigorous
safety reporting, offer the ability to observe and evaluate
long-latency safety events, such as malignancies and car-
diovascular events, as well as short-latency events, such
as infections. Efficacy and safety data from LTE studies
of tofacitinib treatment in global (Study A3921024;
ORAL Sequel) and Japanese (Study A3921041) popula-
tions are part of the largest clinical development pro-
gram undertaken for any RA treatment to date [14–16].
Interim results from the LTE studies have been regu-
larly reported, and final results from Study A3921041,
the LTE study conducted in Japanese patients, have been
published [15]. Here, we report the final data from the
global LTE ORAL Sequel study and describe the safety
and efficacy of treatment with tofacitinib 5 mg and
10mg BID for up to 9.5 years in patients with RA.
Methods
Study design and treatment
ORAL Sequel (NCT00413699; Study A3921024) was an
open-label follow-up LTE study conducted in 414 centers
across 43 countries (further details provided in
Additional file 1: Table S1). Eligible patients had previously
completed a prior qualifying index study of tofacitinib
(Additional file 1: Table S1), which included two phase 1
studies, eight phase 2 studies, and six phase 3 studies.
Across qualifying index studies, tofacitinib was dosed at
1, 3, 5, 10, 15, and 30mg BID, or 20mg once daily, as mono-
therapy or in combination with background csDMARDs
(mostly MTX).
The majority of enrolled patients from phase 2 qualify-
ing index studies initiated open-label tofacitinib at
5 mg BID, and the majority of patients from phase 3
qualifying index studies initiated open-label tofacitinib at10mg BID, except for patients from China who initiated
tofacitinib 5 mg BID as per the protocol. After LTE study
baseline, the tofacitinib dose could be increased or de-
creased at the discretion of the investigator (e.g., in-
creased in the case of inadequate control of RA
symptoms [5 mg to 10 mg BID] or decreased in response
to adverse events [AEs] or laboratory anomalies [10 mg
to 5 mg BID]).
Patients receiving tofacitinib were also eligible for tem-
porary discontinuation if deemed necessary by the inves-
tigator. In addition, patients participating in a vaccine
sub-study (data not reported) underwent temporary
withdrawal from tofacitinib treatment.
Patients were allowed to continue or add stable back-
ground arthritis therapy (including non-steroidal anti-
inflammatory drugs, COX2 inhibitors, and opioids at
≤ 30mg oral morphine/day potency), certain csDMARDs
(MTX, leflunomide, sulfasalazine, anti-malarials, aurano-
fin, and injectable gold preparations at approved doses),
and corticosteroids (≤ 10mg prednisone or equivalent/
day), with adjustment permitted at the investigator’s dis-
cretion for reasons of inadequate efficacy, or tapering/dis-
continuation with disease improvement. Patients taking
MTX must also have been taking folic acid (according to
local standards). Prohibited concomitant medications in-
cluded moderate/potent cytochrome P450 3A4 inhibitors
or inducers.
This study was conducted in accordance with the
International Ethical Guidelines for Biomedical Research
Involving Human Subjects, the Declaration of Helsinki,
and the Good Clinical Practice Guidelines, along with
applicable local regulatory requirements and laws. The
study protocol was approved by the Institutional Review
Boards and/or Independent Ethics Committee at each
study center. An independent Data Safety Monitoring
Board external to the study sponsor reviewed unblinded
safety data on a cumulative basis, and Safety Endpoint
Adjudication Committees, blinded to treatment assign-
ment of prior randomized double-blind index studies,
supported with standardized safety endpoint assessment
for selected events as described below. All patients pro-
vided written, informed consent.
Patients
Patients who met the criteria for the index studies,
which included a diagnosis of RA based on the Ameri-
can College of Rheumatology (ACR) 1987 Revised Cri-
teria, and had completed the index studies were eligible
for enrollment in ORAL Sequel. For those enrolling
> 14 days after completion of their prior qualifying index
study, the investigator must have deemed that their RA
disease activity warranted treatment with tofacitinib and
that no evidence of active or inadequately treated
Mycobacterium tuberculosis infection be present. Key
Wollenhaupt et al. Arthritis Research & Therapy           (2019) 21:89 Page 3 of 18exclusion criteria for this LTE study included the follow-
ing for all patients enrolling from the index studies:
current/recent history of uncontrolled clinically signifi-
cant renal, hepatic, hematologic, gastrointestinal, endo-
crine, pulmonary, cardiac, or neurologic disease; lifetime
history of lymphoproliferative disorder, lymphoma,
leukemia, or signs and symptoms suggestive of lymph-
atic disease; history of recurrent herpes zoster infection,
current human immunodeficiency virus or hepatitis B/C
infection, or any infection requiring hospitalization (in-
cluding herpes zoster), parenteral antimicrobial therapy,
or judged to be opportunistic by the investigator within
6 months prior to the first study drug dose (including
those that occurred during the prior qualifying index
study); current or history of malignancy (with the excep-
tion of adequately treated or excised non-metastatic
basal/squamous cell skin cancer or cervical carcinoma in
situ); or use of prohibited concomitant medications. For
patients enrolling > 14 days after completion of their
prior qualifying index study, additional exclusion criteria
included hemoglobin levels < 9 g/dL or hematocrit < 30%;
absolute white blood cell count < 3.0 × 109/L, absolute
neutrophil count (ANC) < 1.2 × 109/L, or absolute
lymphocyte count (ALC) < 0.5 × 109/L (< 0.75 × 109/L for
patients in Croatia, Czech Republic, Denmark, Ireland,
Korea, Germany, Spain, Sweden, and the UK);
thrombocytopenia (platelet count < 100 × 109/L); esti-
mated creatinine clearance < 40 mL/min (Cockcroft-
Gault calculation); and total bilirubin, aspartate
aminotransferase (AST), or alanine aminotransferase
(ALT) > 1.5 times the upper limit of normal (ULN).
Objectives and endpoints
The primary objective was to determine the long-term
safety and tolerability of tofacitinib 5mg and 10mg BID,
via evaluation of AE reports, clinical laboratory data, phys-
ical examinations, vital signs, and electrocardiogram (ECG)
values. The key secondary objective was to evaluate the
long-term persistence of efficacy with tofacitinib 5mg and
10mg BID, via endpoints including ACR20/50/70 response
rates; observed mean score over time in Health Assessment
Questionnaire-Disability Index (HAQ-DI) and proportion of
patients reporting improvements ≥ the minimum clinically
important difference (≥ 0.22) in HAQ-DI; observed mean
score over time in Disease Activity Score in 28 joints using
erythrocyte sedimentation rate (DAS28-4[ESR]), and propor-
tions of patients achieving DAS28-4(ESR)-defined remission
(scores < 2.6) and DAS28-4(ESR)-defined low disease activity
(LDA; scores ≤ 3.2); and the observed proportions of patients
achieving remission defined by Clinical (CDAI) and Simpli-
fied (SDAI) Disease Activity Indices (scores ≤ 2.8 and ≤ 3.3,
respectively). Exploratory ACR20/50/70 response main-
tenance analyses and CDAI/SDAI remission maintenance
analyses were also conducted.Statistical methods
Statistical analyses of safety and efficacy data are descrip-
tive in nature, and no formal comparisons between
tofacitinib treatment groups were performed.
Baseline values for safety and efficacy endpoints were
those of the qualifying index study (index baseline) for
patients who enrolled in the LTE study within ≤ 14 days
of index study completion, or the LTE baseline for
patients who enrolled > 14 days after index study com-
pletion. The safety analysis set comprised all patients
who received at least one dose of study medication.
Assignment to the tofacitinib 5 mg or 10mg BID arm
for analysis of efficacy and safety outcomes in this LTE
study was based on the study average total daily dose
(TDD) for each patient (i.e., sum of all doses received di-
vided by number of days of treatment over the entire
study duration for each patient): tofacitinib 5 mg BID if
TDD < 15mg and tofacitinib 10 mg BID if TDD ≥ 15 mg.
Patients were assigned to “stay-on monotherapy”
(received tofacitinib monotherapy) or “stay-on background
csDMARDs” (received tofacitinib plus csDMARD
combination therapy) subgroups for analysis of safety out-
comes if they remained on their initial study-start
therapy for the entire duration of the study (irrespective
of tofacitinib or csDMARD dose adjustments), with the
exception of a ≤ 28-day break in csDMARD use allowed
for stay-on csDMARD patients. Patients who switched
from csDMARD to monotherapy, or vice versa, were
not included in these subgroup analyses and, therefore,
they do not sum to total number of patients treated with
tofacitinib. Equivalent subgroup analyses for efficacy
outcomes, including data pooled from ORAL Sequel,
have been previously published [17].
Exposure-adjusted event rates of the number of
patients with events per 100 patient-years (EAERs per 100
patient-years) were calculated for AEs, and incidence
rates of the number of patients with events per 100
patient-years (IRs per 100 patient-years) and 95% confi-
dence intervals (CI; calculated via the Exact Poisson
method) were calculated for AEs of special interest.
EAERs were based on the number of unique patients
with events per 100 patient-years over all patients’ expo-
sures between their first dose of tofacitinib and their last
dose (excluding any temporary treatment breaks in be-
tween). IRs were based on the number of unique
patients with events during the time between the first and
last tofacitinib dose plus 28 days, divided by the time ac-
cruing during the risk period (i.e., between the first and
last tofacitinib dose plus 28 days, or the time accruing to
the first event, whichever occurred earlier). The recur-
rence rate of herpes zoster was also calculated for
patients with at least one event within the risk period.
In relation to IRs for AEs of special interest, cardiovas-
cular events were adjudicated from February 2009,
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events from December 2012, gastrointestinal events
from December 2014, and interstitial lung disease events
from April 2014. Events prior to these dates were not
adjudicated and were identified by clinical review of
AEs. For malignancies, the central histopathological
review of AEs was initiated in July 2009, with events
adjudicated from February 2014. Events prior to this
were subsequently reviewed and adjudicated.
The efficacy analyses were conducted for all patients
who received at least one dose of study medication and
had at least one post-index/LTE baseline efficacy
measurement available. All analyses were based on
observed data with no imputation for missing data.
Results
Patients
Between February 5, 2007, and November 30, 2016,
4481 patients were enrolled in the main study of ORAL
Sequel (Additional file 2: Figure S1a). A total of 2340
patients discontinued (see Kaplan-Meier time to discon-
tinuation curve in Additional file 2: Figure S1b). For all
tofacitinib, the median time to discontinuation was
1785 days (approximately 4.9 years), as estimated by the
Kaplan-Meier method. After 5 years, 49% of patients
were still in the study.
Patient baseline demographic and disease characteris-
tics (Additional file 3: Table S2) were generally similar
between treatment arms. In total, 90.2% (n = 4041/4481)
of patients had baseline data from their index study (i.e.,
patients enrolled ≤ 14 days after index study completion)
and 9.8% (n = 440/4481) had baseline data re-assessed
and reported at the time of enrollment into the LTE
study (i.e., patients enrolled > 14 days after index study
completion).
The majority of patients (76.6% [3432/4481]) remained




AE data are presented for all patients up to month 114
of the LTE period for tofacitinib 5mg and 10mg BID.
Total tofacitinib exposure was 16,291 patient-years
(4683 patient-years in the 5 mg BID population and
11,608 patient-years in the 10 mg BID population). A
summary of all-cause treatment-emergent AEs (hereafter
referred to as AEs), including the most common
all-cause AEs by system organ class (SOC) and preferred
term, is presented in Table 1. The majority of all-cause
AEs were mild (59%) or moderate (36%) in severity for
all tofacitinib; corresponding data for tofacitinib
5 mg BID were 57% and 36%, respectively, and for
tofacitinib 10 mg BID were 59% and 36%, respectively.All-cause adverse events leading to discontinuation
The proportion of patients with all-cause AEs decreased
from baseline over time, while the proportion with
all-cause AEs leading to discontinuation remained con-
sistent over time (Additional file 4: Figure S2). For all
tofacitinib, the most common all-cause AEs by SOC
leading to discontinuation included infections and
infestations (9.4% [n = 423/4481]), investigations (4.6%
[n = 206/4481]), and benign, malignant, and unspecified
neoplasms (3.7% [n = 165/4481]), and by preferred term
included pneumonia (1.8% [n = 80/4481]), blood creatinine
increased (1.5% [n = 69/4481]), and herpes zoster
(0.7% [n = 32/4481]). The IR (95% CI) for all-cause
AEs leading to discontinuation was 6.78 (6.39, 7.20)
for all tofacitinib. The corresponding IR data for
patients receiving tofacitinib as combination therapy
(n = 656/2464) was 7.73 (7.15, 8.35), and for patients
receiving tofacitinib as monotherapy (n = 279/1298)
was 5.88 (5.21, 6.61).Serious adverse events
For all tofacitinib, the most common (≥ 5% in any treat-
ment group) all-cause serious AEs (SAEs) by SOC in-
cluded infections and infestations (9.0% [n = 405/4481])
and musculoskeletal and connective tissue disorders
(5.5% [n = 246/4481]), and by preferred term included
pneumonia (2.1% [n = 96/4481]), osteoarthritis (1.9%
[n = 86/4481]), and RA (0.8% [n = 34/4481]), noting that
1.1% (n = 51/4481) also reported “condition aggravated”
as an SAE. The IR (95% CI) for SAEs was 9.03 (8.55,
9.53) for all tofacitinib. The corresponding SAE IR (95%
CI) for patients receiving tofacitinib as combination
therapy (n = 726/2464) was 9.48 (8.80, 10.20), and for
patients receiving tofacitinib as monotherapy (n = 349/1298)
was 8.11 (7.28, 9.01).Deaths
A total of 88 deaths occurred in the study; 44 within the
risk period (excluding one fetal death [pregnancy in
partner of enrolled patient with in utero fetal death
reported after diagnosis of Down syndrome]) and 43
outside of the risk period. A total number of 84
all-cause SAEs (5 mg BID n = 39, 10 mg BID n = 45)
resulted in death. The IR (95% CI) for all-cause
mortality was 0.26 (0.19, 0.36) for all tofacitinib. The
corresponding all-cause mortality IR (95% CI) for
patients receiving tofacitinib as combination therapy
(n = 23/2464) was 0.27 (0.17, 0.40), and for patients
receiving tofacitinib as monotherapy (n = 18/1298)
was 0.37 (0.22, 0.59). Further details (incidence of
mortality and mortality listings) are provided in
Additional file 5: Table S3.
Table 1 Patients with all-cause treatment-emergent AEs

































Dose reduction only 75 (14.5) 86 (6.5) 161 (8.7)
Temporary discontinuation only 372 (71.8) 1147 (86.3) 1519 (82.2)
Dose reduction and temporary discontinuation 71 (13.7) 96 (7.2) 167 (9.0)
Permanent discontinuationa 275 (53.1) 615 (46.3) 890 (48.2)
AEs, n (%) [EAERs; patients with events per 100 patient-years]
Most frequently reported AEs by SOC (≥ 20% in any treatment group) and within-SOC preferred term (≥ 5% in any treatment group)
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Table 1 Patients with all-cause treatment-emergent AEs (Continued)


































































Safety analysis set: all patients who received at least one dose of study medication. Database lock: March 2, 2017
AE adverse event, ALT alanine aminotransferase, BID twice daily, CI confidence interval, EAER exposure-adjusted event rate, IR incidence rate, SAE serious adverse
event, SOC system organ class
aPatients who had dose reduction or temporary discontinuation due to AEs and eventually discontinued from the study
EAERs represent rates of events/100 patient-years of exposure. Total tofacitinib exposure was 16,291 patient-years (4683 patient-years in the 5 mg BID population
and 11,608 patient-years in the 10mg BID population). Exposure for EAER calculations was 16,113 patient-years for all tofacitinib (4641 patient-years in the
5 mg BID population and 11,472 patient-years in the 10mg BID population). Data for herpes zoster reflect only AEs reported using preferred term “Herpes zoster”
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IRs for all-cause AEs of special interest are summarized in
Table 2, including data for patients receiving tofacitinib as
combination therapy and as monotherapy. The major-
ity of malignancy-, cardiovascular-, mortality-, and
infection-related events had IRs < 0.5; exceptions were
herpes zoster, all serious infections, malignancies ex-
cluding non-melanoma skin cancer (NMSC), and
NMSC. Figure 1a–c presents serious infections, malig-
nancies excluding NMSC, and herpes zoster over
time, showing they remained generally stable. IRs for
malignancies excluding NMSC, lymphoma, melano-
mas, breast cancer (female patients only), lung cancer,
tuberculosis, composite major adverse cardiovascular
event (MACE), gastrointestinal perforation, interstitial
lung disease, deep vein thrombosis (DVT), pulmonary
embolism (PE), and mortality were comparable between
patients receiving tofacitinib 5mg and 10mg BID.
Across all patients, IRs were higher (per non-overlapping
CI) with tofacitinib 10mg BID versus 5mg BID for herpes
zoster (3.7 versus 2.3, respectively) and opportunistic infec-
tions excluding tuberculosis (0.5 versus 0.1); numerical dif-
ferences (per marginally overlapping CI) in IRs were also
observed for all serious infections (Table 2). The majority of
cases of herpes zoster were non-serious (96% [503/526]);
30 patients had recurrent herpes zoster, including 1 patientwith recurrent ophthalmic herpes zoster. The recurrence
rate for herpes zoster (per 100 patient-years) was 2.6.
In addition, IRs were higher for patients receiving
tofacitinib as combination therapy versus monotherapy for
herpes zoster (3.6 versus 2.4, respectively). Within the sub-
group of patients receiving tofacitinib as combination ther-
apy, IRs were higher with tofacitinib 10mg BID versus 5mg
BID for all serious infections (3.0 versus 1.9, respectively),
herpes zoster (4.1 versus 2.2), and opportunistic infec-
tions excluding tuberculosis (0.6 versus 0.0) (Table 2).
Laboratory variables of interest
Laboratory variables of interest, including total cholesterol
and low-density lipoprotein (LDL) (Fig. 2a, b), ALT (Add-
itional file 6: Figure S3a), AST (Additional file 6: Figure
S3b), and serum creatinine (Additional file 6: Figure S3d)
remained generally stable over time, with variability attrib-
utable to smaller patient numbers at later time points.
Changes over time were observed in lymphocytes (ALC
levels gradually declined until month 48, whereafter the
level stabilized; Fig. 2c) and neutrophils (Fig. 2d); further-
more, slight increases in hemoglobin (Additional file 6:
Figure S3c) were observed until month 24, which then
remained stable. Laboratory data are reported up to
month 96 of the LTE study period only, due to low patient












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1 Incidence rates for notable safety events of special interest over time. Including serious infections (a), malignancies excluding NMSC (b),
and herpes zoster (c). IR is the number of patients with events per 100 patient-years. Total tofacitinib exposure was 16,291 patient-years
(4683 patient-years in the 5mg BID population and 11,608 patient-years in the 10mg BID population). Database lock: March 2, 2017. BID twice daily,
CI confidence interval, IR incidence rate, NMSC non-melanoma skin cancer, PY patient-years of exposure





Fig. 2 Mean (SE) laboratory variables of interest over time. Including total cholesterol (a), LDL (b), lymphocyte counts (c), and neutrophil counts
(d). Baseline qualifying index study data were used for approximately 90% of patients. Data for 12-month intervals are reported in the tables.
Database lock: March 2, 2017. BID twice daily, BL baseline, LDL low-density cholesterol, SE standard error
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any time were mild, 1.5 × 103/mm3 ≤ANC < 2 × 103/
mm3, 6.0% (271/4481); moderate, 1.0 × 103/mm3 ≤ANC
< 1.5 × 103/mm3, 1.3% (58/4481); severe, 0.5 × 103/mm3 ≤
ANC < 1.0 × 103/mm3, 0.2% (7/4481); and potentially
life-threatening, ANC < 0.5 × 103/mm3, 0%). No patients
with confirmed neutropenia developed serious infections
within 30 days of their lowest neutrophil count. For
confirmed lymphopenia at any time, values were mild,
1.5 × 103/mm3 ≤ALC < 2 × 103/mm3, 17.5% (782/4481);
moderate, 1.0 × 103/mm3 ≤ALC < 1.5 × 103/mm3, 40.6%
(1820/4481); severe, 0.5 × 103/mm3 ≤ALC < 1.0 × 103/
mm3, 30.1% (1351/4481); and potentially life-threatening,
ALC < 0.5 × 103/mm3, 1.3% (58/4481). Of the patients
with mild, moderate, and severe lymphopenia, 0.9%
(7/782), 0.3% (5/1820), and 0.3% (4/1351), respect-
ively, developed serious infections within 30 days of
their lowest ALC. Of the 58 patients with potentially
life-threatening lymphopenia at any time (with ALC <
0.5 × 103 cells/mm3), five cases were potentially asso-
ciated with serious infections; two (3.4%) occurred
within 30 days of the patients’ lowest ALC. In
addition, 52 of the 58 patients eventually returned to
ALC ≥ 0.5 × 103 cells/mm3, and 29 of the 58 patients
with ALC < 0.5 × 103 cells/mm3 eventually returned to
within 20% of their respective baseline value, follow-
ing treatment discontinuation. For all tofacitinib, the
IRs (95% CI) for neutropenia (n = 86/4481) and
lymphopenia (n = 181/4481) were 0.52 (0.42, 0.65) and
1.11 (0.95, 1.28), respectively.
The proportions of patients with confirmed ALT and
AST > 1×, ≥ 2×, and ≥ 3× ULN are shown in
Additional file 7: Table S4. The IR (95% CI) for ALT
≥ 3× ULN was 1.71 (1.51, 1.92) for all tofacitinib; the
corresponding IR for patients receiving tofacitinib as
combination therapy (n = 133/2464) was 1.59 (1.33, 1.88),
and for patients receiving tofacitinib as monotherapy
(n = 70/1298) was 1.50 (1.17, 1.90). For AST ≥ 3× ULN,Table 3 Summary of actions taken with tofacitinib and MTX during
Patients with ≥ 3× ULN ALT or AST (N = 109), n (%)










to AEsa (n = 2
Permanently discontinued MTX 4 (3.7) 14 (12.8) 1 (0.9)
Temporarily discontinued MTX 1 (0.9) 0 0
Reduced MTX dose 2 (1.8) 0 0
Continued MTX 20 (18.3) 11 (10.1) 0
Patients were not receiving MTX 13 (11.9) 14 (12.8) 1 (0.9)
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, BID
aAEs occurring prior to AST elevations
bReduction in tofacitinib dose from 10mg BID to 5 mg BIDIRs (95% CI) were 0.98 (0.84, 1.15), 1.04 (0.83, 1.28), and
0.93 (0.68, 1.25) for all tofacitinib, patients receiving
tofacitinib as combination therapy (n = 88/2464), and pa-
tients receiving tofacitinib as monotherapy (n = 44/1298),
respectively.
The summary of actions taken with tofacitinib and
MTX during elevated AST or ALT levels ≥ 3× ULN is
shown in Table 3.
For all tofacitinib, laboratory values that met with
protocol criteria for monitoring included any single
ALT and/or AST elevation > 3× ULN regardless of
total bilirubin (7.1% [317/4481]); any single
hemoglobin value < 8.0 g/dL, or one that drops ≥ 2
gm/dL below baseline (14.3% [640/4481]); and transient
increases in serum creatinine > 50% over the average
screening and baseline values leading to discontinuation
(4.5% [201/4481] patients). Of note, no patients had
confirmed ANC < 500 mm3. No clinically notable
changes were observed in systolic or diastolic blood
pressure or ECG values, from baseline to month 96
(data not shown).Efficacy
Efficacy data are presented up to month 96 of the LTE
study period for tofacitinib 5 mg BID, and up to month
72 of the LTE study period for tofacitinib 10 mg BID
(data were censored due to low patient numbers after
these time points; although these patients contributed to
all tofacitinib exposure).ACR
ACR20 (Fig. 3), ACR50 (Additional file 8: Figure S4a),
and ACR70 (Additional file 8: Figure S4b) response rates
were maintained over time between months 1 and 96
and were generally similar with tofacitinib 5 mg (months





same dose (n = 10)
Temporarily discontinued
tofacitinib and resumed
reduced doseb (n = 7)
Reduced
tofacitinib
doseb (n = 11)
1 (0.9) 0 2 (1.8)
0 0 0
0 1 (0.9) 0
4 (3.7) 4 (3.7) 2 (1.8)
5 (4.6) 2 (1.8) 7 (6.4)
twice daily, MTX methotrexate, ULN upper limit of normal
Fig. 3 ACR20 response over time (observed). ACR calculated with respect to qualifying index study data available for approximately 90% of
patients. Italicized data not reported in figure due to low patient numbers. Data for 12-month intervals are reported in the table. Database lock:
March 2, 2017. ACR American College of Rheumatology, BID twice daily
Fig. 4 Mean (SE) HAQ-DI scores over time (observed). Baseline qualifying index study data were used for approximately 90% of patients. Italicized
data not reported in figure due to low patient numbers. Data for 12-month intervals are reported in the table. Database lock: March 2, 2017.
BID twice daily, BL baseline, HAQ-DI Health Assessment Questionnaire-Disability Index, SE standard error
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Fig. 5 Mean (SE) DAS28-4(ESR) over time (observed). Baseline qualifying index study data were used for approximately 90% of patients.
Italicized data not reported in figure due to low patient numbers. Data for 12-month intervals are reported in the table. Database lock: March 2,
2017. BID twice daily, BL baseline, DAS28-4(ESR) Disease Activity Score in 28 joints using erythrocyte sedimentation rate, SE standard error
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Acknowledging appreciable attrition in the sample size
over time, improvements in mean HAQ-DI scores at
month 1 remained stable over time with tofacitinib 5 mg
and 10mg BID (Fig. 4). HAQ-DI ≥ 0.22 improvement
from baseline was observed in 64.8% (n = 103/159) of
patients with all tofacitinib at month 96; in 63.6%
(n = 91/143) of patients with tofacitinib 5 mg BID at
month 96; and in 70.3% (n = 201/286) of patients with
tofacitinib 10 mg BID at month 72.
DAS28-4(ESR), CDAI, and SDAI
Mean DAS28-4(ESR) (Fig. 5) decreased at month 1 and
then remained consistent over time with tofacitinib 5mg
and 10mg BID. DAS28-4(ESR)-defined remission was
observed in 24.7% (n = 39/158) of patients with all
tofacitinib at month 96, in 25.4% (n = 36/142) of patients
with tofacitinib 5 mg BID at month 96, and in 25.0%
(n = 71/284) of patients with tofacitinib 10mg BID at
month 72. Corresponding data for DAS28-4(ESR)-defined
LDA were 46.8% (n = 74/158), 47.2% (n = 67/142), and
48.2% (n = 137/284), respectively.
CDAI- and SDAI-defined remission was observed in
approximately a third of patients at month 96
(Additional file 9: Figure S5a and S5b). Rates of CDAI
and SDAI remission were maintained over time, withthe majority (> 85%) of patients maintaining or im-
proving their CDAI or SDAI category (CDAI ≤ 2.8;
2.8 < CDAI ≤ 10; CDAI > 10) from the end of their
index study to month 96 of the LTE.
Discussion
The ORAL Sequel LTE study of tofacitinib is part of
the largest clinical development program undertaken
for any RA treatment to date. Up to 9.5 years of
treatment with tofacitinib in more than 4000
patients worldwide with RA is represented in this
study, with a combined tofacitinib exposure of > 16,000
patient-years.
Safety data up to 114months for all tofacitinib, and
efficacy data up to 96 months for tofacitinib 5 mg BID
and 72months for 10 mg BID, are reported, with low
patient numbers limiting interpretation beyond these
time points. Patient baseline demographic and disease
characteristics were generally similar between the tofacitinib
5 mg and 10 mg BID treatment arms, although a greater
proportion of patients enrolled from prior phase 3
studies compared with phase 2 studies and then initi-
ated the LTE at 10 mg BID, per protocol (the exception
to this was that all phase 3 patients from China initiated
the LTE at 5 mg BID, also per protocol). Most (> 90%)
patients were enrolled in the LTE study within ≤ 14 days
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data were used, per protocol.
In all, the safety profile remained consistent with that
observed in prior phase 2 [2–6] or phase 3 [7, 9–13]
tofacitinib studies, or prior combined analyses including
LTE data [16, 18]. The IRs for AEs leading to discon-
tinuation were comparable for all tofacitinib, tofacitinib
5 mg BID, and tofacitinib 10 mg BID (6.8, 6.7, and 6.8,
respectively), as were the IRs for SAEs (9.0, 8.2, and 9.4,
respectively). Overall in ORAL Sequel, 52% of patients
discontinued by month 114 (24% due to AEs and
4% due to insufficient clinical response) and the incidence
of AEs leading to discontinuation remained stable over
time. These data are consistent with a recent integrated
analysis of safety data over 8.5 years for tofacitinib (5mg
and 10mg BID combined, with or without background
csDMARDs) across 17 phase 1/2/3 studies and two LTE
studies, including ORAL Sequel, in which the IR for
discontinuation due to AEs was 7.5 and the IR for SAEs
was 9.0, for all tofacitinib [18]. Furthermore, in pooled
LTE safety analyses from ORAL Sequel and Japanese
Study A3921041 (tofacitinib 5mg and 10mg BID com-
bined, with or without background DMARDs), 51% of
patients discontinued by month 114 (24% due to AEs
and 4% due to insufficient clinical response) and the IR
for SAEs was 9.1 for all tofacitinib [16].
Most malignancy-, cardiovascular-, mortality-, and
infection-related events had IRs < 0.5; exceptions were her-
pes zoster, all serious infections, malignancies excluding
NMSC, and NMSC. IRs for herpes zoster, all serious infec-
tions, and malignancies excluding NMSC remained gener-
ally stable over time. Recurrent herpes zoster was observed
in 30 patients. IRs were higher (CI non-overlapping) with
tofacitinib 10mg BID versus 5mg BID for herpes zoster
and opportunistic infections excluding tuberculosis and
numerically higher (CI marginally overlapping) for all ser-
ious infections; no dose-dependencies were indicated for
other events.
Infections and infestations were anticipated to repre-
sent the most common class of overall AEs. IRs for ser-
ious infections were consistent between ORAL Sequel,
the integrated analysis of safety data for tofacitinib [18],
and pooled ORAL Sequel and Study A3921041 data
[16], at 2.4, 2.7, and 2.5, respectively, as were IRs for
herpes zoster between ORAL Sequel and the integrated
analysis of safety data, at 3.4 and 3.9, respectively (data
not reported for the pooled ORAL Sequel and Study
A3921041 analysis; IR was 7.4 for herpes zoster in the
Japanese population of Study A3921041 alone [15]).
With respect to tuberculosis, the IR for all tofacitinib
(0.2) was slightly lower compared with the IR for other
opportunistic infections excluding tuberculosis (0.4) in
ORAL Sequel. In the integrated analysis of safety data
for tofacitinib, IRs were similar between tuberculosis(0.2) and other opportunistic infections excluding tuber-
culosis (0.3), and concordant with ORAL Sequel data
[18]. Prior evaluation has supported the understanding
that the risk of tuberculosis in patients receiving tofacitinib
treatment directly varies with background tuberculosis
prevalence in different geographic sub-populations [19].
ORAL Sequel IR data for tuberculosis are comparable with
data for biologic DMARDs [20–22].
Of interest, the long-latency events MACE and lymph-
oma had IRs at 0.4 and 0.1, respectively. IRs for other AEs
of interest reported in both ORAL Sequel and the inte-
grated analysis of safety data for tofacitinib [18] were
consistent: 0.8 and 0.9 for malignancies excluding NMSC,
0.7 and 0.6 for NMSC, and both 0.1 for gastrointestinal
perforation (which is also comparable with tumor necrosis
factor inhibitors [TNFi] [23]). Furthermore, the IRs for
DVT and PE in patients receiving tofacitinib (both 0.1)
were comparable to those reported in data pooled from
phase 2 and phase 3 studies of tofacitinib as monotherapy
or in combination with DMARDs (DVT IR of 0.1 for both
tofacitinib 5 and 10mg BID, and PE IR of 0.1 for tofacitinib
5mg BID and 0.2 for tofacitinib 10mg BID [24]) and in the
literature for patients with RA, including those treated with
DMARDs (DVT IRs of 0.45 [25] and 0.62 [26], and PE IRs
of 0.26 [25] and 0.20 [26]).
In support of the consistencies noted above, safety
data from LTE studies and meta-analyses of biologic and
targeted synthetic DMARDs are comparable with those
reported for tofacitinib. Considering discontinuation
from biologic DMARDs, 62% of patients discontinued
by year 10 of treatment in an LTE study of adalimumab
(23% due to AEs and 12% due to lack of efficacy/disease
progression) [27]; and 31% of patients discontinued by
year 5 in an LTE study of subcutaneous abatacept
(31% due to AEs and 7% due to lack of efficacy) [28]. Con-
sidering safety events of special interest, previous LTE
studies have reported IRs for serious infections of 3.1 and
1.7 events for adalimumab (across 10 years of treatment)
and subcutaneous abatacept (across 5 years of treat-
ment), respectively [27, 28]. In the integrated analysis of
safety data for baricitinib, event IRs were reported
for serious infections (3.0), herpes zoster (3.3),
tuberculosis (0.1), MACE (0.5), DVT (0.4), PE (0.2), malig-
nancies excluding NMSC (0.8), lymphoma (0.08), NMSC
(0.4), and gastrointestinal perforation (0.04) [29, 30].
Meta-analysis data showed that in a dataset comprising
RCTs and LTE studies, the IRs for tofacitinib (serious infec-
tion 2.74; malignancies excluding NMSC 0.89) were com-
parable to those reported for biologic and targeted
synthetic DMARDs, including abatacept, adalimumab, bari-
citinib, certolizumab pegol, etanercept, golimumab,
infliximab, rituximab, and tocilizumab (serious infection
3.04–7.59; malignancies excluding NMSC 0.75–1.06) [31, 32],
which in turn are concordant with data reported for
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tofacitinib were observed to be congruous with IRs previ-
ously calculated in a 2017 meta-analysis of RCTs for
biologic DMARDs, including abatacept (3.0), rituximab (3.5),
tocilizumab (5.4), and TNFi (5.5), and the targeted
synthetic DMARD baricitinib (4.8 for 2mg, 3.7 for 4mg)
[31]. Taking the findings of ORAL Sequel and these data
together, this supports the work of other groups con-
cluding that the rates of serious infections for tofacitinib
are within the range of those reported for biologic
DMARDs (up to 12 weeks only) [33] and the targeted
synthetic DMARD, baricitinib (versus placebo) [29].
AE data in ORAL Sequel indicated some differences
between tofacitinib monotherapy and combination ther-
apy. IRs for AEs leading to discontinuation in ORAL
Sequel were higher (CI non-overlapping) in patients
receiving tofacitinib combination therapy (7.7) compared
with patients receiving tofacitinib monotherapy (5.9);
SAE IRs were also numerically different (CI marginally
overlapping) between patients receiving combination
therapy (9.5) and tofacitinib monotherapy (8.1). In terms
of AEs of special interest, IRs were higher (CI
non-overlapping) in patients receiving tofacitinib as
combination therapy versus monotherapy for herpes
zoster. Within the subgroup of patients receiving
tofacitinib as combination therapy, IRs were higher (CI
non-overlapping) with tofacitinib 10 mg BID versus 5 mg
BID for all serious infections, herpes zoster, and oppor-
tunistic infections excluding tuberculosis.
Laboratory variables of interest, including cholesterol,
LDL, ALT, AST, and serum creatinine, remained generally
stable over time. ALC levels gradually declined until month
48, whereafter the level stabilized. Overall, 40.6% of patients
experienced moderate lymphopenia, and 30.1% of patients
experienced severe lymphopenia; these events did not meet
with study discontinuation criteria, per protocol. Approxi-
mately 1% of patients had a drop in lymphocyte count to
< 500 cells/mm3 (potentially life-threatening lymphopenia);
however, nearly all recovered to above 500 cells/mm3 upon
treatment discontinuation. Additionally, five of these
patients experienced a serious infection during the study;
two occurred within 30 days of the patients’ lowest lympho-
cyte count. Although the proportion of patients who
developed a serious infection within 30 days of the lowest
lymphocyte count was highest among patients with poten-
tially life-threatening lymphopenia, these results should be
interpreted with caution due to the low number of
patients with ALC < 500 cells/mm3. As per the tofacitinib
prescribing information, routine clinical practice should
involve evaluation of lymphocyte count at baseline, moni-
toring every 3months during tofacitinib treatment, and
consideration of the following actions: discontinuation if
ALC reaches < 500 cells/mm3 (a level associated with in-
creased risk of serious infections [18, 34]), dose reductionor interruption if ALC reaches 500–750 cells/mm3, and
dose maintenance if ALC is ≥ 750 cells/mm3 [35, 36].
Clinically meaningful improvements in the signs and
symptoms of RA as measured by ACR response rates,
DAS28-4(ESR) improvements from baseline, and CDAI-
and SDAI-defined remission rates, as well as improve-
ments in physical functioning as measured by HAQ-DI
improvements from baseline, were also maintained over
time in patients who remained on tofacitinib treatment.
Efficacy data for patients receiving tofacitinib monother-
apy or tofacitinib plus csDMARD combination therapy
were not available here, but have been previously pub-
lished [17]; in this earlier analysis of data pooled from
ORAL Sequel and Study A3921041, efficacy was main-
tained through to month 72, regardless of treatment
regimen.
It is acknowledged that LTE studies are limited by
enrolling eligible patients who completed preceding
index studies and excluding those who developed
tofacitinib treatment-related SAEs and so were dis-
continued from preceding index studies. As per the
protocol, significant opportunistic infections or ser-
ious infection events, and certain malignancies, pre-
cluded enrollment to ORAL Sequel. LTE study
populations, therefore, represent patients in whom
the study drug is known to be efficacious and well
tolerated, restricting full evaluation of the benefit to
risk profile. It is important to note that a greater exposure
(patient-years) occurred with tofacitinib 10mg BID
compared with 5 mg BID, as a result of the majority
of patients enrolling from large phase 3 studies and
initiating the LTE study at 10 mg BID per protocol
(except for patients from China, bringing a geo-
graphic skew). Caution should be taken when inter-
preting results for patients with the longest tofacitinib
exposure due to the relatively small patient numbers
at later months. Furthermore, tofacitinib dose assign-
ment based on using average TDD does not account
for cumulative treatment exposure or dose changes
over time. It also does not provide the actual dose when
the event occurred; therefore, although 77% of patients
remained on their study-start dose, this may have atten-
uated any between-dose differences for the 5 mg versus
10 mg BID tofacitinib dose. We also recognize that there
may be limitations to the interpretation of efficacy
results, given that all analyses were conducted “as
observed” and patients not achieving an effect on treat-
ment in the qualifying study were more likely to not en-
roll in the LTE study or discontinue. To this point, it
should be noted that only < 4% of patients discontinued
from the LTE study due to insufficient clinical response.
The lack of a placebo or comparator arm also restricts
benefit to risk profile evaluation. Finally, comparisons of
data for combination versus monotherapy should be
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index study defined the regimen for all patients
within that study, and patients were not random-
ized to dose for the LTE study or to one regimen
versus the other (monotherapy versus combination
therapy). The monotherapy subgroup was also
smaller (n = 1298) than the combination therapy
subgroup (n = 2464).
Nevertheless, open-label LTE studies provide valuable
information. A controlled setting with rigorous safety
reporting, including independent adjudication of events, is
facilitated. Data for drug exposure are collected over
months or years, yielding a long-term safety profile. In-
deed, additional long-term studies of tofacitinib are on-
going: Study A3921133 (NCT02092467), an ongoing
post-marketing surveillance study, was initiated to
compare the safety of tofacitinib versus TNFi in
patients with RA in an open-label design. With final
enrollment estimated at ~ 4400 patients, outcomes are
event-driven, with malignancies excluding NMSC and
the incidence of MACE being the primary outcome
measures. Study A3921133 is, therefore, anticipated to
provide further insights that will contribute further to
the evaluation of the benefit to risk profile of
tofacitinib. Furthermore, a recent publication on
post-marketing surveillance experience with tofacitinib
showed that no new safety risks were revealed in this
real-world setting compared with the safety profile
identified in the RA clinical development program
[37]. As of December 2017, it is estimated that over
115,000 patients with RA worldwide have received
tofacitinib (Pfizer data on file).Conclusions
Tofacitinib 5 mg and 10 mg BID demonstrated a con-
sistent safety profile and sustained efficacy in this
open-label LTE ORAL Sequel study of patients with
RA. Safety data are reported up to 9.5 years, and
efficacy data up to 8 years, based on adequate patient
numbers to support conclusions. Observed IRs for
SAEs, serious infections, malignancies, MACE, DVT,
and PE were similar to those observed in pooled data
from phase 1, 2, 3, and LTE studies, and comparable
to those seen with TNFi and other biologic DMARDs.
Patient-level laboratory safety data were consistent
with findings from prior tofacitinib phase 2, phase 3,
and LTE studies. Furthermore, the safety profile of
tofacitinib in patients who initiated tofacitinib as
monotherapy was generally similar to that observed
when tofacitinib was initiated in combination with
csDMARDs. Tofacitinib 5 mg and 10 mg BID provided
sustained improvement in signs and symptoms of RA
and improvements in physical function.Additional files
Additional file 1: Table S1. Summary of qualifying index studies
associated with ORAL Sequel (NCT00413699).
Additional file 2: Figure S1. Patient disposition (a) and discontinuation
over time (b). aFour patients in the tofacitinib 10 mg BID arm had a
missing end-of-study page. bEvaluable for AEs (evaluable for laboratory
data: tofacitinib 5 mg BID n = 1118, tofacitinib 10 mg BID n = 3346, and
all tofacitinib n = 4464). cTwo patients in the tofacitinib 10 mg BID arm
did not have recorded AEs. Safety analysis set: all patients who received
at least one dose of study medication; efficacy analysis set: all patients
who received at least one dose of study medication and had at least one
post-baseline efficacy measurement available. Time to discontinuation:
difference between the end-of-study date and first tofacitinib dose date
plus 1 day; completers are censored at the end-of-study date. Study
discontinuation occurred with the following scenarios: serious infections
requiring antimicrobial therapy or hospitalization; opportunistic infections
judged to be significant by the investigator; two sequential lymphocyte
or neutrophil counts < 500 mm3 (neutrophil counts < 1000 mm3 for
patients from Croatia, Czech Republic, Denmark, Germany, Ireland, Korea,
Spain, Sweden, and the UK); two sequential platelet counts < 75,000 mm3;
two sequential AST or ALT elevations > 3 times the ULN with ≥ 1 total
bilirubin value > 2 times the ULN, abnormal International Normalized Ratio
liver function test, or symptoms consistent with hepatic injury (or elevations
> 5 times the ULN regardless); single positive HBcAb and a negative HBsAb;
two sequential hemoglobins < 8.0 g/dL or a decrease > 30% from baseline;
two sequential increases in serum creatinine > 100% of the average
baseline/screening values (> 50% for Korea); other serious or severe AEs.
Database lock: March 2, 2017. AE adverse event, ALT alanine
aminotransferase, AST aspartate aminotransferase, BID twice daily,
HBcAb hepatitis B core antibody, HBsAb hepatitis B surface antibody,
ULN upper limit of normal.
Additional file 3: Table S2. Patient baseline demographic and disease
characteristics.
Additional file 4: Figure S2. All-cause AEs (a) and all-cause AEs leading
to discontinuation (b) over time. Baseline qualifying index study data
were used for approximately 90% of patients. Database lock: March 2,
2017. AE adverse event, BID twice daily.
Additional file 5: Table S3. Incidence of all mortality (a) and mortality
listings (b).
Additional file 6: Figure S3. Mean (SE) ALT (a), AST (b), hemoglobin (c),
and serum creatinine (d) over time. Baseline qualifying index study data
were used for approximately 90% of patients. Data for 12-month intervals
are reported in the tables . Database lock: March 2, 2017. ALT alanine
aminotransferase, AST aspartate aminotransferase, BID twice daily,
SE standard error.
Additional file 7: Table S4. Confirmed AST and ALT > 1×, ≥ 2×, and
≥ 3× ULN.
Additional file 8: Figure S4. ACR50 (a) and ACR70 (b) response rates
over time (observed). ACR calculated with respect to qualifying index
study data available for approximately 90% of patients. Italicized data not
reported in figure due to low patient numbers. Data for 12-month intervals
are reported in the tables. Database lock: March 2, 2017. ACR American
College of Rheumatology, BID twice daily.
Additional file 9: Figure S5. Remission as defined by CDAI (score ≤ 2.8)
(a) and SDAI (score ≤ 3.3) (b) (observed). Baseline qualifying index study
data were used for approximately 90% of patients. Italicized data not
reported in figure due to low patient numbers. Data for 12-month
intervals are reported in the tables. Database lock: March 2, 2017.
BID twice daily, BL baseline, CDAI Clinical Disease Activity Index,
SDAI Simplified Disease Activity Index, SE standard error.Abbreviations
ACR: American College of Rheumatology; AE: Adverse event; ALC: Absolute
lymphocyte count; ALT: Alanine aminotransferase; ANC: Absolute neutrophil
count; AST: Aspartate aminotransferase; BID: Twice daily; BL: Baseline;
BMI: Body mass index; CDAI: Clinical Disease Activity Index; CI: Confidence
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modifying antirheumatic drug; DAS28-4(ESR): Disease Activity Score in 28
joints using erythrocyte sedimentation rate; DMARD: Disease-modifying
antirheumatic drug; EAER: Exposure-adjusted event rate;
ECG: Electrocardiogram; ESR: Erythrocyte sedimentation rate; HAQ-DI: Health
Assessment Questionnaire-Disability Index; HBcAb: Hepatitis B core antibody;
HBsAb: Hepatitis B surface antibody; IR: Incidence rate; LDA: Low disease
activity; LDL: Low-density cholesterol; LTE: Long-term extension; MACE: Major
adverse cardiovascular event; MTX: Methotrexate; NMSC: Non-melanoma skin
cancer; PY: Patient-years of exposure; Q2W: Every 2 weeks; QD: Once daily;
RA: Rheumatoid arthritis; RCT: Randomized controlled trial; SAE: Serious
adverse event; SC: Subcutaneous; SD: Standard deviation; SDAI: Simplified
Disease Activity Index; SE: Standard error; SOC: System organ class;
TDD: Total daily dose; TNFi: Tumor necrosis factor inhibitor; ULN: Upper limit
of normal
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